1 / 1

Breaking Down the Latest Clinical Trials on Binimetinib

Explore the cutting-edge advancements in medical research with our in-depth analysis of the latest clinical trials on Binimetinib. Uncover the groundbreaking findings and potential implications for patient care. At ImpoMed Healthcare, we strive to provide you with timely and comprehensive insights into the evolving landscape of pharmaceutical innovation, empowering healthcare professionals and enthusiasts alike. <br>For more inquiry click on this link :- https://www.impomedhealthcare.com/<br>

impo
Download Presentation

Breaking Down the Latest Clinical Trials on Binimetinib

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. BINIMETINIB Home | Cancer | Solid Tumors | BINIMETINIB BINIMETINIB Tablets Description Composition Dosage Indications MEKTOVI (binimetinib) is a kinase inhibitor. MEKTOVI (binimetinib) tablets for oral use contain 15 mg of binimetinib with the following inactive ingredients: lactose monohydrate, microcrystalline cellulose, croscarmellose sodium, magnesium stearate (vegetable source), and colloidal silicon dioxide. The coating contains polyvinyl alcohol, polyethylene glycol, titanium dioxide, talc, ferric oxide yellow, and ferrosoferric oxide. Copyright © 2024 ImpoMed Convert web pages and HTML files to PDF in your applications with the Pdfcrowd HTML to PDF API Printed with Pdfcrowd.com

More Related